^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Hexalen (altretamine)

i
Other names: ENT 50852, HXM, NSC 13875, SAE9, KB 913
Associations
Trials
Company:
Eisai, Ipsen
Drug class:
Alkylating agent
Associations
Trials
1year
Battling colorectal cancer via s-triazine-based MMP-10/13 inhibitors armed with electrophilic warheads for concomitant ferroptosis induction; the first-in-class dual-acting agents. (PubMed, Bioorg Chem)
s-Triazine was rationalized as the core inspired by altretamine, an FDA-approved ferroptosis inducer...The complex-induced intracellular iron overload, depleted GSH with a relative fold decrement of 0.12, consequently triggering lipid peroxidation and ferroptosis by a 3.94 relative fold increment. Collectively, 9d could be a lead for tuning MMPs selectivity and ferroptosis induction potential to maximize the benefit of such a combination.
Journal
|
GPX4 (Glutathione Peroxidase 4)
|
Hexalen (altretamine)
1year
A review on the research progress of traditional Chinese medicine with anti-cancer effect targeting ferroptosis. (PubMed, Chin Med)
Several small-molecule compounds exhibit anti-tumor effects through ferroptosis, including sorafenib and altretamine, which induce ferroptosis by inhibiting System-Xc and GPX4 respectively, but many problems, such as poor druggability, still exist. In this study, we elucidated the underlying mechanisms of ferroptosis, and the anti-tumor pharmacology of TCM targeting ferroptosis including prescriptions, Chinese herbs, extracts, and natural compounds. Our findings might act as valuable reference for research on anti-tumor drugs targeting ferroptosis, especially those drugs developed from TCM.
Review • Journal
|
GPX4 (Glutathione Peroxidase 4) • TFRC • ACSL4 (Acyl-CoA Synthetase Long Chain Family Member 4) • SLC7A11 (Solute Carrier Family 7 Member 11) • AIFM2 (Apoptosis Inducing Factor Mitochondria Associated 2)
|
sorafenib • Hexalen (altretamine)
over1year
Antitumor Activity of s-Triazine Derivatives: A Systematic Review. (PubMed, Molecules)
To date, three s-triazine derivatives, including altretamine, gedatolisib, and enasidenib, have already been approved for refractory ovarian cancer, metastatic breast cancer, and leukemia therapy, respectively, demonstrating that the s-triazine core is a useful scaffold for the discovery of novel anticancer drugs. The medicinal chemistry of s-triazine derivatives as anticancer agents was summarized, including discovery, structure optimization, and biological applications. This review will provide a reference to inspire new and original discoveries.
Review • Journal
|
gedatolisib (PF-05212384) • Idhifa (enasidenib) • Hexalen (altretamine)